Here’s a fun bit of pharmaceutical trivia: the peptide that eventually became an FDA-approved treatment for low female libido was never supposed to be about sex at all.
In the 1980s, researchers at the University of Arizona were trying to build a better sunless tan — a peptide that could darken skin without UV exposure, potentially reducing skin cancer risk.
They developed Melanotan I and its more potent cousin, Melanotan II, both synthetic mimics of alpha-melanocyte-stimulating hormone (α-MSH), the natural hormone that triggers pigment production.
Then something unexpected happened. During early human trials of Melanotan II for erectile dysfunction, male volunteers kept reporting spontaneous, unplanned erections.
In one double-blind study, Melanotan II triggered erections in 17 of 20 men, compared to just 3 of 20 on placebo. Researchers realized they’d stumbled onto something much bigger than a tanning drug — a peptide that could flip a switch in the brain’s arousal circuitry.
That discovery led a company called Palatin Technologies to isolate the specific fragment of Melanotan II responsible for the arousal effect, without the pigmentation side effects.
They called it PT-141. Its generic name is bremelanotide, and in 2019 it became the first FDA-approved, non-hormonal treatment for low sexual desire in women — sold under the brand name Vyleesi.
So the three peptides are really one family tree: Melanotan I and II (the tanning originals) gave rise to PT-141 (the refined, FDA-approved descendant). Same molecular neighborhood, very different regulatory fates.
How PT-141 actually works
This is the part people get wrong most often. Drugs like Viagra work on blood flow — they’re plumbers. PT-141 works on the brain — it’s more like an electrician.
PT-141 activates melanocortin receptors (mainly MC4R) in the hypothalamus, the brain region that governs motivation and drive. This, in turn, nudges dopamine pathways associated with wanting and desire.
Critically, it doesn’t touch estrogen, progesterone, or testosterone — it works on the neurological “I want this” signal rather than the hormonal machinery. That’s why it can help women whose hormone levels are technically normal but whose desire has simply gone quiet.
It’s taken as-needed, roughly 45 minutes before anticipated intimacy, as a subcutaneous injection (an auto-injector, not a pill).
What the actual research shows
This is where PT-141 pulls ahead of almost every other “libido peptide” circulating online: it has real, peer-reviewed, placebo-controlled human data behind it.
The RECONNECT trials — the pivotal Phase 3 studies that got PT-141 approved — were two identically designed, randomized, double-blind, placebo-controlled trials involving more than 1,200 premenopausal women diagnosed with hypoactive sexual desire disorder (HSDD). Women received either 1.75 mg of bremelanotide or placebo, self-administered before sex, over 24 weeks.
The results:
- Both trials showed statistically significant improvements in sexual desire (measured by the Female Sexual Function Index–Desire domain) and in desire-related distress, compared to placebo.
- Roughly 25% more women on bremelanotide experienced a clinically meaningful jump in desire compared to those on placebo.
- The effect wasn’t dramatic on paper (a modest shift in scale scores), but for women living with persistent, distressing low desire, it was meaningful in daily life — which is exactly what a follow-up “exit study” found: women who’d taken bremelanotide described real increases in desire, physical arousal, and overall quality of their sex lives, in a way that placebo simply didn’t replicate.
- A 52-week open-label extension (following the original trials) found the desire and distress improvements held up over the long haul, with continued use.
- The most common side effects were nausea (about 40% of users, often mild and decreasing over time), flushing, and headache — a well-characterized safety profile from a formally studied, monitored drug program.
Sources
- Clayton, A.H., et al. (2016). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. PubMed
- Koochaki, P., Revicki, D., Wilson, H., et al. (2021). The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results. Journal of Women’s Health. PubMed
- Revicki, D.A., Althof, S.E., Derogatis, L.R., et al. (2020). Reliability and validity of the elements of desire questionnaire in premenopausal women with hypoactive sexual desire disorder. Journal of Patient-Reported Outcomes. NCBI
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. (2019). Obstetrics & Gynecology, 134(5), 909-917. PubMed
- Clayton, A.H., Kingsberg, S.A., Portman, D., et al. (2022). Safety Profile of Bremelanotide Across the Clinical Development Program. Journal of Women’s Health, 31(2), 171-182.
- ClinicalTrials.gov. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (RECONNECT, NCT02333071 and NCT02338960). ClinicalTrials.gov
- Peptides.org. Melanotan 2: Reviews, Clinical Trials, and Safety — overview of MC1/MC3/MC4 receptor activity and the original double-blind erectile-response study. Peptides.org
- The Metabolic Journal. Melanotan II: What It Is, Safety Concerns, and FDA Warnings. The Metabolic Journal
- FDA prescribing information for Vyleesi (bremelanotide) — dosing limits (1 dose/24 hrs, max 8/month) and approved indication.
This article is for general educational purposes and isn’t medical advice. The products for sale on this site are for research purposes only, not intended for human use. Talk to a licensed clinician before starting any treatment for low sexual desire.